Item 5. Other Information
ITEM
5. OTHER INFORMATION.
None.
23
ITEM
6. EXHIBITS.
The
following exhibits are filed as part of, or incorporated by reference into, this quarterly report on Form 10-Q:
No.
Description
of Exhibit
3.1.1
Amended
and Restated Memorandum and Articles of Association of Silexion Therapeutics Corp (formerly Biomotion Sciences) (incorporated by reference
to Exhibit 3.1 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on August 21, 2024)
3.1.2
Ordinary
Resolution Effecting 1-for-9 Reverse Share Split to Share Capital of Silexion Therapeutics Corp (incorporated by reference to Exhibit
3.1 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on November 29, 2024)
3.1.3
Ordinary
Resolution Effecting 1-for-15 Reverse Share Split to Share Capital of Silexion Therapeutics Corp (incorporated by reference to Exhibit
3.1 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on July 29, 2025)
3.1.4
Ordinary
Resolution Effecting 1-for-10 Reverse Share Split to Share Capital of Silexion Therapeutics Corp (incorporated by reference to Exhibit
3.1 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on May 29, 2026)
3.1.5
Ordinary
Resolution Approving Increase in Authorized Share Capital to $121,500 (9,000,000 ordinary shares, par value $0.0135) (incorporated by
reference to Exhibit 3.1 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on August 19, 2025)
3.1.6
Ordinary
Resolution Approving Increase in Authorized Share Capital to $796,500 (59,000,000 ordinary shares, par value $0.0135) (incorporated by
reference to Exhibit 3.1 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on May 5, 2026)
3.1.7
Ordinary
Resolution Approving Increase in Authorized Share Capital to $2,146,500 (15,900,000 ordinary shares, par value $0.135) (incorporated by
reference to Exhibit 3.1 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on July 21, 2026)
31.1*
Certification
of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302
of the Sarbanes-Oxley Act of 2002
31.2*
Certification
of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302
of the Sarbanes-Oxley Act of 2002
32.1**
Certification
of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**
Certification
of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*
Inline XBRL Instance
Document.
101.SCH*
Inline XBRL Taxonomy
Extension Schema Document.
101.CAL*
Inline XBRL Taxonomy
Extension Calculation Linkbase Document.
101.DEF*
Inline XBRL Taxonomy
Extension Definition Linkbase Document.
101.LAB*
Inline XBRL Taxonomy
Extension Label Linkbase Document.
101.PRE*
Inline XBRL Taxonomy
Extension Presentation Linkbase Document.
104*
Cover Page Interactive
Data File (formatted as Inline XBRL and contained in Exhibit 101).
*
Filed herewith.
**
Furnished herewith.
24
SIGNATURES
Pursuant
to the requirements of Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
SILEXION
THERAPEUTICS CORP
Date: August 14, 2026
/s/ Ilan Hadar
Name:
Ilan Hadar
Title:
Chairman and Chief Executive
Officer
(Principal Executive
Officer)
Date: August 14, 2026
/s/ Mirit Horenshtein-Hadar
Name:
Mirit Horenshtein-Hadar
Title:
Chief Financial Officer
(Principal Financial
and Accounting Officer)
25
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.